Compare Ascendis Pharma A/S (ASND) vs Boeing Co (BA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Boeing Co — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Boeing Co trades at $219.37 (market cap $175.22B). The key difference: Boeing Co is far larger — about 9.9× Ascendis Pharma A/S's market cap, and Boeing Co pays a 0.03% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BA | |
|---|---|---|
Market Cap | $17.74B | $175.22B |
Sector | Health | Industrials |
52-Week High | $277.18 | $252.15 |
52-Week Low | $163.32 | $179.12 |
Enterprise Value | $18.11B | $201.53B |
Volume | — | 7,591,579 |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Boeing (BA) trades at $222.28, down 0.37% on the day, with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with 2025 revenue of $89.46B and net income of $2.24B, reversing previous losses. Recent news includes both positive developments like new aircraft orders and regulatory milestones, alongside ongoing safety concerns highlighted by recent incidents.
The outlook is cautiously optimistic with a $268.33 consensus price target representing 21% upside. Key opportunities include production expansion and defense contracts, while risks center on operational execution, debt burden, and persistent safety-related headline volatility that could impact investor confidence and regulatory timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →
